Initial Evidence in Thromboangiitis Obliterans (Buerger’s Disease) Treatment with Bosentan - European Medical Journal

Initial Evidence in Thromboangiitis Obliterans (Buerger’s Disease) Treatment with Bosentan

Download PDF
Joaquín de Haro, Silvia Bleda, Francisco Acin

No potential conflict of interest.

EMJ Cardiol. ;1[1]:96-100. DOI/10.33590/emjcardiol/10311101.
Thromboangiitis obliterans, endothelin, endothelial dysfunction, bosentan, nitric oxide

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Thromboangiitis obliterans (TAO) is a vascular disease that affects small and medium-sized arteries and veins of both upper and lower extremities. Distal ischaemic lesions and digital necrotic ulcers, as well as major amputation rates, among these patients are not negligible. So far, no treatment option has been demonstrated to be completely effective for this disease. Endothelin-1 (ET-1) has been increasingly associated to vascular damage. Furthermore, elevated levels of ET-1 have been proved in TAO patients. Thus, ET-1 receptor antagonists may be considered as a treatment option in this disease.

Consistently, initial results from open-label studies or case reports show promising efficacy of bosentan for treatment and prevention of digital ulcers in TAO with a favourable safety profile. In any case, bosentan should be further investigated in TAO patient management. To confirm initial promising findings, larger controlled randomised trials with a control group are needed. In the meantime, bosentan should be considered as a hopeful investigational agent for treating these patients.

Please view the full content in the pdf above.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally